Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | GGT1 | P19440 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7196935 | 0.94 | FOLH1 (0.57) | FOLH1GGT1CPB2GSRRNPEP | |
| SCHEMBL8768872 | 0.82 | FOLH1 (0.47) | FOLH1GGT1CPB2GSRRNPEP | |
| SCHEMBL4951210 | 0.82 | GGT1 (0.65) | FOLH1GGT1CPB2GSRRNPEP | |
| SCHEMBL7198357 | 0.82 | FOLH1 (0.47) | FOLH1GGT1CPB2GSRRNPEP | |
| SCHEMBL146727 | 0.82 | GGT1 (0.55) | FOLH1GGT1CPB2GSRRNPEP | |
| SCHEMBL6890284 | 0.82 | GGT1 (0.55) | FOLH1GGT1CPB2GSRRNPEP | |
| SCHEMBL4951214 | 0.82 | GGT1 (0.65) | FOLH1GGT1CPB2GSRRNPEP | |
| SCHEMBL28538677 | 0.81 | FOLH1 (0.51) | FOLH1GGT1CPB2GSRSLC6A5 | |
| SCHEMBL22776222 | 0.81 | FOLH1 (0.51) | FOLH1GGT1CPB2GSRSLC6A5 | |
| SCHEMBL22776223 | 0.81 | FOLH1 (0.51) | FOLH1GGT1CPB2GSRSLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602910-B2 | Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine | ILEX ONCOLOGY, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | ILEX ONCOLOGY, INC. (US) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | DHODH, DDT, HADHB | FOLH1 39/4885GGT1 547/4885CPB2 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.